Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 7/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822972 | 0.85 | NPC1 (0.46) | BRS3KCNH2NPC1RXFP1CYP11B1 | |
| SCHEMBL1844388 | 0.81 | CCR1 (0.46) | NPC1CYP11B1CYP11B2AURKAABL1 | |
| SCHEMBL1842465 | 0.79 | MAOB (0.53) | L3MBTL1 | |
| SCHEMBL9805398 | 0.79 | RAB9A (0.51) | NPC1CYP11B1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL9805528 | 0.79 | RAB9A (0.51) | NPC1CYP11B1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL19407055 | 0.79 | SMN1; SMN2 (0.56) | BRS3KCNH2NPC1RXFP1CYP11B1 | |
| SCHEMBL9805437 | 0.78 | RAB9A (0.61) | NPC1CYP11B1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL9805471 | 0.78 | RAB9A (0.65) | NPC1CYP3A4SMN1; SMN2RAB9ATP53 | |
| SCHEMBL9805639 | 0.78 | RAB9A (0.65) | NPC1CYP3A4SMN1; SMN2RAB9ATP53 | |
| SCHEMBL65960 | 0.77 | TAAR1 (0.50) | KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| EP-2083623-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008051405-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051405-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | BRS3 1/4885KCNH2 1063/4885NPC1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.